---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-314364"
form_type: "8-K"
ticker: "AARD"
cik: "0001774857"
company_name: "Aardvark Therapeutics, Inc."
filed_at: "2025-12-10T23:59:59+00:00"
generated_at: "2026-05-16T13:39:21.684185+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aardvark doses first patient in Australia Phase 3 HERO trial; Q3 2026 data readout on track

## Summary
- First patient dosed in Australia in Phase 3 HERO trial for ARD-101 for hyperphagia in Prader-Willi syndrome.
- Regulatory clearance received for clinical trial sites in Canada and UK; EU sites not needed for full enrollment.
- All patients completing the 12-week HERO trial have enrolled in the Open Label Extension, indicating strong patient interest.
- Topline data readout remains on track for Q3 2026 driven by strong US enrollment and international progress.

## SEC filing metadata
- accession: 0001193125-25-314364
- form_type: 8-K
- ticker: AARD
- cik: 0001774857
- company_name: Aardvark Therapeutics, Inc.
- filed_at: 2025-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1774857/000119312525314364/0001193125-25-314364-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1774857/000119312525314364/ck0001774857-20251210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-314364
- JSON: https://secwatch.observer/filing/0001193125-25-314364.json
- Plain text: https://secwatch.observer/filing/0001193125-25-314364.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.